Acurx presents ibezapolstat Phase 2 clinical trial results in CDI

Acurx announced that results from the ibezapolstat Phase 2 clinical trial in patients with C. difficile Infection – CDI – were presented at the 34th Congress of ESCMID Global on April 30th held in Barcelona. Dr. Eugenie Basseres, Research Scientist, University of Houston College of Pharmacy, stated: “These findings show that ibezapolstat’s unique mechanism of activity, inhibition of DNA polymerase IIIC, translates into in vitro activity against C. difficile strains with reduced susceptibility to fidaxomicin and vancomycin. As antimicrobial-resistant strains continue to emerge in the community, ibezapolstat will become a valuable therapeutic option. These data reinforce earlier findings related to the anti-recurrence properties of ibezapolstat and warrant further development in Phase 3 trials with further microbiome studies planned to confirm the mechanisms behind these clinical findings”. The complete Phase 2 results are being prepared for submission to a prominent scientific journal.